Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04037566
Other study ID # V2.1
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 2019
Est. completion date August 2024

Study information

Verified date July 2019
Source Xijing Hospital
Contact Guangxun GAO, Dr.
Phone +86 29 84775203
Email gaoguangxun@fmmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first-in-human trial proposed to test CD19-specific CAR-T cells with edited endogenous HPK1 (XYF19 CAR-T cells) in patients with relapsed or refractory CD19+ leukemia or lymphoma. This is an investigational study designed as a single-center, open-label and single-arm clinical trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date August 2024
Est. primary completion date August 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Subject must meet all the following criteria to be selected:

1. Willing to provide consent/assent for participation in the study by patient or his/her legal guardian;

2. Male or Female subjects age =18 and =55 years;

3. Evidence of relapsed/refractory CD19+ B cell hematological malignancies. The most common relapsed/refractory B cell hematological malignancies include: (1) B cell acute lymphoblastic leukemia (B-ALL); (2) B cell lymphomas, including indolent B cell lymphoma (CLL, FL, MZL, LPL, HCL) and aggressive B cell lymphoma (DLBCL, BL, MCL);

4. Subjects (20 subjects of B cell acute lymphoblastic leukemia and 20 subjects of B cell lymphoma) with the following conditions:

1. Failure to achieve complete remission (CR) after at least two lines of standard chemotherapy while not suitable for HSCT (auto/allo-HSCT);

2. Relapse after CR, but not eligible for HSCT (auto/allo-HSCT);

3. Failure to achieve remission or relapse after HSCT;

5. Leukemia patient confirmed by bone marrow aspiration that has not been alleviated; lymphoma patient with measurable or assessable lesions;

6. Adequate organ function:

1. Liver: ALT/AST = 3 × ULN, total bilirubin =34.2 mol/L;

2. Kidney: Creatinine<220 µmol/L, creatinine clearance rate (CCR) = 60 mL/min;

3. Lung: arterial oxygen saturation =95%;

4. Heart: Left ventricular ejection fraction (LVEF) =40%;

5. Absolute lymphocyte count (ALC) = 100/µL, absolute neutrophil count (ANC) = 1,000/µL, platelets (PLT) = 75,000/µL;

7. No prior anti-cancer therapy, including chemotherapy, radiotherapy, immunotherapy (immunosuppression) within 4 weeks prior to enrollment, and toxic reactions of all prior treatments recovered to grade =1 at the time of enrollment (except for low toxicity such as alopecia);

8. Presence of smooth peripheral superficial venous blood flow to fulfill intravenous infusion;

9. Karnofsky performance score =60; ECOG =2; estimated survival =3 months.

Exclusion Criteria:

- Subjects meeting one or more of the following criteria will be excluded:

1. Female patient who is pregnant or breastfeeding ;

2. Male or Female patient within Pregnancy Program in 1 year;

3. Unwilling or unable to guarantee effective contraceptive measures (condoms or contraceptives) within 1 year after enrollment;

4. Presence of uncontrolled infectious disease within 4 weeks prior to enrollment:

5. Active hepatitis B or hepatitis C infection;

6. HIV infection;

7. Active TB;

8. Presence of active malignancy other than disease under study, confirmed by pathology;

9. Severe autoimmune diseases or immunodeficiency;

10. Suffering from allergies;

11. Joining another clinical trial within 6 weeks prior to enrollment;

12. Using systemic corticosteroid within 4 weeks prior to enrollment (except for those who use inhaled steroids);

13. Psychiatric disorders;

14. History of epilepsy and seizures or other CNS pathology;

15. Addiction to or abuse of drugs;

16. Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
XYF19 CAR-T cell
Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
Drug:
Cyclophosphamide
A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
Fludarabine
A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.

Locations

Country Name City State
China Xijing Hospital Xi'an Shannxi

Sponsors (2)

Lead Sponsor Collaborator
Xijing Hospital Xi'An Yufan Biotechnology Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The adverse events associated with XYF19 CAR-T cells product will be assessed. Determine safety profile of a single infusion of XYF19 CAR-T cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Occurrence of study related adverse events defined as NCI CTCAE v5.0 > grade 3 possibly, probably, or definitely related to study treatment. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to adverse event. 30 days
Primary Maximum tolerated dose (MTD) as determined by dose limiting toxicity (DLT). The MTD is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT). The dose limiting toxicity is defined as CTCAE grades non-reversible grade 3, or any grade 4-5 allergic reactions related to the study cell infusion; CTCAE grades non-reversible grade 3, or any grade 4-5 autoimmune reactions related to the study cell infusion; or CTCAE grades non-reversible non-hematologic grade 3, or any grade 4-5 organ toxicity (cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic) not pre-existing or due to the underlying malignancy and occurring within 30 days of study product infusion related to study cell infusion. The study will employ a standard 3+3 design to find the MTD of XYF19 CAR-T cells dose. 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT03415399 - Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma Phase 1
Withdrawn NCT03605589 - Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Phase 1
Recruiting NCT04807881 - Phase Ib Clinical Study of Keynatinib Phase 1
Completed NCT05510596 - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome N/A
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Terminated NCT02670317 - Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. Phase 2
Completed NCT00998946 - Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Phase 2
Terminated NCT00768339 - A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas Phase 1/Phase 2
Terminated NCT00521638 - Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma Phase 1
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Completed NCT00379574 - Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL Phase 1/Phase 2
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Completed NCT00147121 - Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Phase 2/Phase 3
Recruiting NCT04594798 - A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL Phase 2
Recruiting NCT04161248 - Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Early Phase 1
Withdrawn NCT04052061 - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT04884035 - Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma Phase 1
Not yet recruiting NCT05834426 - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Recruiting NCT05376709 - A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population N/A